Highmark, a Pittsburgh-based licensee of the Blue Cross Blue Shield Association, announced it has entered into an outcomes-based contract with UCB Inc. for certolizumab pegol (Cimzia). The tumor necrosis factor blocker is approved for use in adults with chronic inflammatory conditions such as Crohn’s disease, plaque psoriasis and psoriatic and rheumatoid arthritis.
The agreement, for the health care professional–administered injection formulation of the